Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Clint A. Stalnecker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0570-4416; OpenAlex author ID A5005237041; NIH RePORTER profile ID 10997467. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
62
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 2 papers, 1 grant · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 5 papers

Papers 20

  1. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2026.117627↗
  2. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  3. Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer. Co-author DOI 10.1172/jci191370↗
  4. Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.06.28.734981↗
  5. KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.01.756025↗
  6. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. First author DOI 10.1126/scisignal.adu7145↗
  7. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adt5511↗
  8. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1757↗
  9. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Co-author DOI 10.1158/0008-5472.can-25-1507↗
  10. Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance Co-author DOI 10.64898/2025.12.01.691471↗
  11. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  12. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  13. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0391↗
  14. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. Co-author DOI 10.18632/genesandcancer.231↗
  15. Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancer. Co-author DOI 10.1080/15548627.2022.2042782↗
  16. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Co-author DOI 10.1158/0008-5472.can-21-1443↗
  17. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2021.109291↗
  18. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Co-author DOI 10.1016/j.celrep.2021.110060↗
  19. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. First author DOI 10.1038/s41591-020-0947-8↗
  20. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. First author DOI 10.1038/s41591-019-0368-8↗

Grants 1

  1. Defining the contributions of WT RAS in RAS-mutant lung cancer F32CA232529↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Channing J. Der · 15 shared papers, 2019–2026 · strength 2.36
  2. Kirsten L. Bryant · 13 shared papers, 2019–2026 · strength 2.17
  3. Adrienne D. Cox · 13 shared papers, 2019–2026 · strength 1.92
  4. Mariaelena Pierobon · 8 shared papers, 2019–2026 · strength 1.12
  5. Andrew M. Waters · 8 shared papers, 2019–2026 · strength 1.04
  6. Craig M. Goodwin · 7 shared papers, 2021–2026 · strength 1.02
  7. Jennifer E. Klomp · 8 shared papers, 2019–2026 · strength 1.00
  8. Kristina Drizyte‐Miller · 6 shared papers, 2021–2025 · strength 0.99
  9. Jonathan M. DeLiberty · 5 shared papers, 2021–2026 · strength 0.88
  10. A. Cole Edwards · 5 shared papers, 2021–2026 · strength 0.80
  11. Bjoern Papke · 7 shared papers, 2019–2026 · strength 0.77
  12. Andrew J. Aguirre · 4 shared papers, 2021–2026 · strength 0.69
  13. J. Nathaniel Diehl · 6 shared papers, 2019–2026 · strength 0.69
  14. Emanuel F. Petricoin · 4 shared papers, 2023–2025 · strength 0.69
  15. Lee M. Graves · 4 shared papers, 2021–2026 · strength 0.66
  16. Ryan N. Robb · 3 shared papers, 2025–2026 · strength 0.64
  17. Mallory K. Roach · 3 shared papers, 2025–2026 · strength 0.64
  18. G. Aaron Hobbs · 5 shared papers, 2019–2026 · strength 0.63
  19. Emanuel F. Petricoin · 5 shared papers, 2019–2025 · strength 0.56
  20. Priya S. Hibshman · 3 shared papers, 2021–2026 · strength 0.46
  21. Tikvah K. Hayes · 4 shared papers, 2019–2026 · strength 0.41
  22. Sarah E. Ackermann · 2 shared papers, 2025–2026 · strength 0.40
  23. Michael F. Coleman · 2 shared papers, 2022 · strength 0.39
  24. Timothy Paul Heffernan · 2 shared papers, 2025–2026 · strength 0.36
  25. Zheng Zhong · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.